Resource Summary Report

Generated by RRID on Sep 1, 2026

NCI-H838

RRID:CVCL_1594
Type: Cell Line

Proper Citation

RRID:CVCL_1594

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1594

Proper Citation: RRID:CVCL_1594

Description: Cell line NCI-H838 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: PMID:1311061, PMID:8806092, PMID:11030152, PMID:18083107, PMID:20164919, PMID:20215515, PMID:22460905, PMID:22961666, PMID:25714623, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29444439, PMID:29681454, PMID:30894373, PMID:31068700, PMID:31803961, PMID:31978347, PMID:35839778

Comments: Karyotypic information: Has lost chromosome Y (PubMed=25714623)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H838

Synonyms: H838, H-838, NCIH838

Cross References: BTO:BTO_0003239, CLO:CLO_0008121, EFO:EFO_0002307, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5844, BioGRID_ORCS_Cell_line:517, BioSample:SAMN03471317, BioSample:SAMN10987750, cancercelllines:CVCL_1594,

CCRID:3101HUMSCSP588, Cell_Model_Passport:SIDM01150, ChEMBL-Cells:CHEMBL3308122, ChEMBL-Targets:CHEMBL1075547, CLS:305097, Cosmic:687830, Cosmic:877239, Cosmic:877414, Cosmic:903580, Cosmic:910399, Cosmic:980968, Cosmic:1032440, Cosmic:1802315, Cosmic:1870278, Cosmic:2042864, Cosmic:2630411, Cosmic-CLP:910399, DepMap:ACH-000416, EGA:EGAS00001000978, GDSC:910399, GEO:GSM206500, GEO:GSM274794, GEO:GSM274822, GEO:GSM513966, GEO:GSM514352, GEO:GSM784196, GEO:GSM794302, GEO:GSM827482, GEO:GSM887448, GEO:GSM888528, GEO:GSM1374765, GEO:GSM1374766, GEO:GSM1670268, IARC_TP53:25039, IARC_TP53:30215, IGRhCellID:NCIH838, KCB:KCB 2021016YJ, LiGeA:CCLE_510, LINCS_LDP:LCL-1623, NCI-DTP:NCI-H838, PharmacoDB:NCIH838_1142_2019, PRIDE:PXD030304, Progenetix:CVCL_1594, PubChem_Cell_line:CVCL_1594, Wikidata:Q54908128

ID: CVCL_1594

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234743+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H838.

No alerts have been found for NCI-H838.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. Frontiers in immunology, 17, 1805950.

Mi W, et al. (2026) LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer. Cell reports, 45(6), 117487.

Fu R, et al. (2026) Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. bioRxiv : the preprint server for biology.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Scholler J, et al. (2025) Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer. bioRxiv : the preprint server for biology.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. Cell reports, 44(6), 115722.

Kotagiri S, et al. (2024) Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. Cell chemical biology, 31(12), 2069.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. Cancer immunology research, 12(4), 491.

Mao C, et al. (2024) Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers. Molecular cell, 84(10), 1964.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. eLife, 12.

Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(17), 3855.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Aboulkassim T, et al. (2023) A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. Cell reports, 42(9), 113104.

Tsai JW, et al. (2022) FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. Cancer research, 82(17), 2980.

Spears ME, et al. (2022) De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. Cell reports, 40(13), 111415.

Luo X, et al. (2022) Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. iScience, 25(3), 103985.

Su H, et al. (2021) Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer cell, 39(5), 678.

Ippolito MR, et al. (2021) Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Developmental cell, 56(17), 2440.

Hadi K, et al. (2020) Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell, 183(1), 197.

Chen X, et al. (2020) Identification and Target-Modification of SL-BBI: A Novel Bowman-Birk Type Trypsin Inhibitor from Sylvirana latouchii. Biomolecules, 10(9).